5-132589662-A-G
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_005732.4(RAD50):āc.1277A>Gā(p.Gln426Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000168 in 1,602,748 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005732.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.1277A>G | p.Gln426Arg | missense_variant | Exon 9 of 25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.980A>G | p.Gln327Arg | missense_variant | Exon 10 of 26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152216Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000139 AC: 34AN: 244864Hom.: 0 AF XY: 0.000143 AC XY: 19AN XY: 132456
GnomAD4 exome AF: 0.000170 AC: 247AN: 1450414Hom.: 0 Cov.: 31 AF XY: 0.000173 AC XY: 125AN XY: 720954
GnomAD4 genome AF: 0.000144 AC: 22AN: 152334Hom.: 0 Cov.: 32 AF XY: 0.000161 AC XY: 12AN XY: 74502
ClinVar
Submissions by phenotype
not provided Uncertain:3
The RAD50 c.1277A>G (p.Gln426Arg) variant has been reported in the published literature in individuals with breast and/or ovarian cancer (PMIDs: 34371384 (2021), 33471991 (2021) see also LOVD (https://databases.lovd.nl/shared/variants/RAD50), 32854451 (2020), 31921681 (2019), 31159747 (2019), 30441849 (2018)), including male breast cancer (PMID: 31512090 (2019)). Additionally, this variant has been seen in reportedly healthy individuals (PMIDs: 33471991 (2021) see also LOVD (https://databases.lovd.nl/shared/variants/RAD50), 24894818 (2014)). The frequency of this variant in the general population, 0.00028 (35/126948 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
- -
RAD50 has been only recently described in association with cancer predisposition and the risks are not well understood. This variant is denoted RAD50 c.1277A>G at the cDNA level, p.Gln426Arg (Q426R) at the protein level, and results in the change of a Glutamine to an Arginine (CAA>CGA). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. RAD50 Gln426Arg has not been observed at significant allele frequency in the NHLBI Exome Sequencing Project. This variant is a semi-conservative substitution in which a a neutral polar amino acid is replaced with a positive polar one, altering a position that is well conserved throughout evolution and is not located in a known functional domain. Multiple in silico algorithms predict that this variant may be damaging to protein structure and function. On a molecular level, the impact of this missense variant on protein structure and function is not known and thus we consider this to be a variant of uncertain significance. Furthermore, based on the currently available information, cancer risks associated with this variant, and the RAD50 gene, remain unclear. -
Hereditary cancer-predisposing syndrome Uncertain:3
The p.Q426R variant (also known as c.1277A>G), located in coding exon 9 of the RAD50 gene, results from an A to G substitution at nucleotide position 1277. The glutamine at codon 426 is replaced by arginine, an amino acid with highly similar properties. This variant has been reported in multiple studies of individuals with suspected hereditary breast and/or ovarian cancer syndrome, including patients with male breast cancer, ovarian cancer, and bilateral breast cancer (Urhammer N and Bignon YJ. "Abstract# 3037: Contribution of the Rad50, Mre11A, and NBN genes to HBOC." Cancer Res.2009;69; Koczkowska M et al. Cancers (Basel), 2018 Nov;10;442; Oliver J et al. Front Oncol., 2019 Dec;9:1429; Scarpitta R et al. Breast Cancer Res. Treat., 2019 Dec;178:557-564; Tsaousis GN et al. BMC Cancer, 2019 Jun;19:535; Fanale D et al. Cancers (Basel), 2020 Aug;12:E2415). However, in another study, this variant was not observed in 1313 cases diagnosed with breast cancer before the age of 45 but was reported in 1/1123 controls (Damiola F et al. Breast Cancer Res. 2014 Jun;16:R58). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 426 of the RAD50 protein (p.Gln426Arg). This variant is present in population databases (rs145428112, gnomAD 0.03%). This missense change has been observed in individual(s) with a personal and/or family history of breast, ovarian, pancreatic cancer, and/or renal cell carcinoma (PMID: 30441849, 31512090, 31921681, 32854451, 34371384, 38127826). ClinVar contains an entry for this variant (Variation ID: 127993). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt RAD50 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Nijmegen breakage syndrome-like disorder Uncertain:3
- -
- -
- -
not specified Uncertain:1
Variant summary: RAD50 c.1277A>G (p.Gln426Arg) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00014 in 244864 control chromosomes, predominantly at a frequency of 0.00026 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in RAD50 causing Nijmegen Breakage Syndrome-Like Disorder (0.00014 vs 0.0024), allowing no conclusion about variant significance. c.1277A>G, has been reported in the literature as a VUS and/or reporting conflicting interpretations of pathogenicity in settings of multigene panel testing among individuals with a personal- or family history of Breast and/or Ovarian Cancer, and other tumor phenotypes (example, Koczkowska_2018, Scarpitta_2019, Oliver_2019, Tsaousis_2019, Bono_2021), however it was also found in controls (Haiman_2013, Damiola_2014). These report(s) do not provide unequivocal conclusions about association of the variant with Nijmegen Breakage Syndrome-Like Disorder. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23555315, 24894818, 30680046, 30441849, 31159747, 31512090, 31921681, 34371384, 34201956, 32658311, 30541756, 26689913, 37558543, 30376426, 34299313, 26787654, 28102005, 38127826, 32854451). ClinVar contains an entry for this variant (Variation ID: 127993). Based on the evidence outlined above, the variant was classified as uncertain significance. -
RAD50-related disorder Uncertain:1
The RAD50 c.1277A>G variant is predicted to result in the amino acid substitution p.Gln426Arg. This variant has been reported in an individual undergoing hereditary cancer testing (Tsaousis et al. 2019. PubMed ID: 31159747, Table S5), in an individual with bilateral breast cancer (Fanale et al. 2020. PubMed ID: 32854451), in an individual with hereditary breast and ovarian cancer (Oliver et al. 2019. PubMed ID: 31921681, Table S1), in at least one individual with ovarian cancer (Koczkowska et al. 2018. PubMed ID: 30441849, Table S1), and in an individual with male breast cancer, pancreatic cancer, and bladder cancer (Scarpitta et al. 2019. PubMed ID: 31512090, Table 1). These studies interpreted this variant as uncertain significance. It is reported in 0.028% of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/127993/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Familial cancer of breast Uncertain:1
This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 426 of the RAD50 protein (p.Gln426Arg). This variant is present in population databases (rs145428112, gnomAD 0.03%). This missense change has been observed in individual(s) with a personal and/or family history of breast, ovarian, and/or pancreatic cancer (PMID: 30441849, 31512090, 31921681, 32854451, 34371384) . Five clinical diagnostic laboratories have submitted clinicalsignificance assessments for this variant to ClinVar (Variation ID:127993) after 2014 without evidence for independent evaluation, and all of them classified the variant as uncertain significance. Multiple in silico algorithms predict that this variant may be damaging to protein structure and function.. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at